Avenue Therapeutics (ATXI)
(Delayed Data from NSDQ)
$2.48 USD
+0.14 (5.77%)
Updated Aug 9, 2024 03:45 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Avenue Therapeutics, Inc. [ATXI]
Reports for Purchase
Showing records 21 - 40 ( 41 total )
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
1Q Recap: IV Tramadol PDUFA on October 10; Takeout Closure in Less Than One Year; Raise PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
No Major Impact from COVID-19 Expected on IV Tramadol''s FDA Approval; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
We Expect IV Tramadol''s FDA Approval by PDUFA Date on October 10, 2020; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
Avenue Files IV Tramadol NDA as Expected; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
3Q Recap: NDA Filing on Track; Approval Expected by Year End 2020; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
IV Tramadol Shows Superior Safety and Efficacy Over Oral Tramadol.
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
2Q19 NDA Filing of IV Tramadol by Year End on Track; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
IV Tramadol Hits on Second Pivotal Pain Study; NDA Filing by Year End; Raise PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
1Q19 Recap; Final Phase 3 Readout for IV Tramadol in the Coming Weeks; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
Top-line Data in Mid-2019 a Key Step Towards InvaGen Takeout
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
InvaGen Stock Purchase Complete, Adds Two Board Seats; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
First Patient Dosed in Second Pivotal Phase 3 IV Tramadol Trial; Topline Data Readout in Mid-2019
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
Company: Avenue Therapeutics, Inc.
Industry: Medical - Drugs
InvaGen Deal Is a Much Better Outcome Than Many Had Feared; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Unclassified
Company: Avenue Therapeutics, Inc.
Industry: Unclassified
2Q Review: Second IV Tramadol Phase 3 Study to Start in 2H18; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Avenue Therapeutics, Inc.
Industry: Unclassified
A Unique Opioid Sparing Solution for Post-Op Pain; Initiate Buy, $11 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E